Thursday, September 20, 2012

Pharma consolidation.................


The Global Pharma industry is undergoing huge challenges in terms of innovation and product development, as the federal agencies are decreasing their allocation for R&D and the only option left for the big pharma daddy's is to go for consolidation and thus further creating non-profit organization, which will be in place to accelerate the development of new medicines. Last decade only we had seen TAP alliance (Takeda and Abbott) which had success story of its own. Now the top ten pharmaceutical companies like Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi are consolidating their activity to identify and solve common drug development challenges with the end goals of improving the quality of life by developing novel drugs acting on Novel pathways. We Still have a ray of hope that there will be new drugs which will help us to live better life by fighting in and out with any sort of disease 

No comments:

Post a Comment